REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMA

Overview of attention for article published in Hematological Oncology, June 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 8 Mendeley

So far, Altmetric has seen 1 X post from an account with 10,403 followers.

PROMISING CLINICAL DATA FROM DOSE ESCALATION IN A PHASE IB/II ONGOING STUDY OF MOSUNETUZUMAB WITH POLATUZUMAB VEDOTIN FOR RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMA https://t.co/AP2oZnDNUj

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.